Skip to main content
OpenTrials

Clinical trial condition

Lymphoma

Explore clinical trials studying Lymphoma. Study availability and eligibility vary by location and protocol.

2,141 public trials 305 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma trial results

Completed

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

NCT00670358

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT03484702

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Local Institution - 101 Vienna, Austria
  • Local Institution - 351 Ghent, Belgium
  • Local Institution - 551 Helsinki, Finland
  • Local Institution - 202 Lille, France
View all 20 locations
View Trial Details
Completed

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00243087

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +25 more
Locations
  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • UNMC Eppley Cancer Center at the University of Nebraska Medical Center Omaha, Nebraska, United States
  • James P. Wilmot Cancer Center at University of Rochester Medical Center Rochester, New York, United States
  • M. D. Anderson Cancer Center at University of Texas Houston, Texas, United States
View Trial Details
Completed

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526

Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site New York, United States
  • Research Site Columbus, Ohio, United States
View Trial Details
Completed

A Study of People With CD30 Positive Lymphoma in China

NCT05506774

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +5 more
Locations
  • Anhui Provincial Cancer Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
  • Union Hospital AffiliatedProf to Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, China
View Trial Details

Related conditions